InsiderInsights Daily Ratings Report: October 14, 2020
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in immunology, inflammation and oncology. The company has four clinical-stage product candidates: GB001 (Prostaglandin D2 receptor 2 Antagonist), which is for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions; GB002 (Platelet-derived growth factor Receptor Kinase Inhibitor), which is for the treatment of pulmonary arterial hypertension; GB004 (Hypoxia inducible factor-1a Stabilizer), which is for the treatment of inflammatory bowel disease; and GB1275 (CD11b Modulator), which is for the treatment of oncology indications.
Selecta Biosciences is a biopharmaceutical company using its ImmTOR? platform, designed to induce tolerance to biologic therapies that would otherwise be limited by immunogenicity to treat rare and serious diseases. The company's product candidate, SEL-212, is a combination of a therapeutic uricase enzyme (pegadricase) and its ImmTOR platform that is designed to control serum uric acid levels in patients with chronic refractory gout through monthly administration. The company is applying its ImmTOR platform to mitigate the formation of anti-drug antibodies when dosing gene therapy. The company's investigational gene therapy program targets the treatment of rare genetic diseases, including methylmalonic acidemia.
Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.
Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.
InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.